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The original At Risk Mental State (ARMS) construct (also termed as the Clinical High-Risk state for psychosis, CHR-P) was introduced two decades ago, in 1996 ADDIN EN.CITE 1, to enable identification of subjects at enhanced “imminent development of a first-episode psychotic disorder” (page 964 in2). Since then, the explosion of interest in the literature has been remarkable to the point that the specialist CHR-P provision is currently being recognized as an important component of the clinical services for early psychosis intervention (e.g. NICE guidelines3; NHS England Access and Waiting Time (AWT) standard4). After about two decades of research, new knowledge has been gained that may inform a revision of the CHR-P paradigm. Three substantial conceptual advancements are summarized below.

Risk enrichment and the impact of recruitment strategies
The use of CHR-P criteria is associated with high prognostic accuracy (AUC at 38 months = 0.9) that is comparable to other paradigms of preventative medicine5, leading to correct 38-month disease prediction in approximately one-third of the cases (26%)5, a risk that peaks in the initial two years and then plateaus6. However, the CHR-P criteria yield successful predictive results only if they are applied to selected samples of individuals5. Indeed, recent evidence suggests that significant psychosis risk enrichment occurs before the CHR-P assessment (15% pre-test risk at 38 months ADDIN EN.CITE 7, for details see8). For example, applying CHR-P criteria to samples with a lower pre-test risk of psychosis (e.g ADDIN EN.CITE 9) may substantially dilute the prognostic accuracy of the paradigm and eventually lead to negative findings in the research studies (e.g ADDIN EN.CITE 10, see also table 2 in the study5 for more examples). Within help-seeking individuals undergoing CHR-P assessment, the pre-test risk of psychosis is substantial (15 of 26 [58%])11 and heterogeneous (95%CI 9%-24%) ADDIN EN.CITE 7. It is thus crucial to understand the factors that may modulate it. Recent studies have highlighted that recruitment strategies ADDIN EN.CITE 7 and outreach campaigns ADDIN EN.CITE 7, 12 may impact the pretest risk enrichment. Specifically, individuals referred by first episode and inpatient mental health services have a high pretest risk 13. These findings advance knowledge indicating that CHR-P assessment should primarily be offered to selected samples of individuals “already distressed by mental problems and seeking help for them” (EPA recommendation n.4 ADDIN EN.CITE 14). Stratification of these subgroups11 may inform outreach campaigns, subsequent testing13 and optimize the psychosis prediction. 

Specificity for psychosis prediction
Whether the CHR-P indicates specifically the risk for future psychosis, or to the nonspecific deterioration in mental health, including other non-psychotic disorders, is of paramount relevance for both clinical and research perspectives. Recent studies have confirmed that CHR-P individuals are not at risk for developing incident bipolar disorders, nonbipolar mood disorders or anxiety disorders ADDIN EN.CITE 15 and that the vast majority of comorbid disorders observed in CHR-P individuals who do not develop psychosis is already present at the baseline16. These findings advance knowledge indicating that the possible outcomes specifically associated with the CHR-P (which may be preferred to the acronym “CHR” to better acknowledge the specificity for psychosis prediction) designation may include the onset of psychotic disorders, remission or persistence of initial symptoms and variable functional outcomes ADDIN EN.CITE 17 but not an increased risk of emergence of new non-psychotic mental disorders. 

Heterogeneity of psychosis risks within CHR-P subgroups
Despite the immense research on reliable markers that can predict the subsequent onset of psychosis among CHR-P individuals, researchers are yet to discover such a holy grail18. If the CHR-P category is heterogeneous, this may hamper the ongoing efforts to identify reliable markers for clinical practice. A recent meta-analysis has elucidated the extent by which the three different CHR-P subgroups of Attenuated Psychotic Symptoms (APS), Brief and Limited Intermittent Psychotic Symptoms (BLIPS or BIPS) and Genetic Risk and Deterioration Syndrome (GRD) (for details see ADDIN EN.CITE 19) can be considered as belonging to a single CHR-P group. There was a significantly higher transition risk in the BLIPS subgroup, compared to the other CHR-P subgroups (i.e. BLIPS: 39% vs. APS: 19% at 24 months)20. These findings indicate that the BLIPS and APS subjects may represent distinct subgroups within the CHR-P category20. Furthermore, there was no prognostic difference between the GRD subgroup and the patients assessed but not deemed at risk for psychosis up to 4-year follow-up20 (familiar risk may still be associated with an increased risk of psychosis ADDIN EN.CITE 21 over longer intervals). This raised concerns about the validity of GRD as a state risk criterion for the CHR-P, suggesting more precise alternatives22. 

Contributions of this special issue 
The current special issue advances current knowledge on deconstructing the CHR-P paradigm across its three subgroups and piloting alternative approaches. 

The first study23 focuses on the diagnostic and prognostic significance of the BLIPS. Although the founders of the CHR-P have recommended comparing BLIPS with operationally-based ICD/DSM psychotic disorders (page 706 in  ADDIN EN.CITE 24), no studies have been published to date. The study identified that at baseline, two-thirds (68%) of BLIPS met the criteria for ICD-10 “Acute and Transient Psychotic Disorder” (ATPD), mostly featuring schizophrenic symptoms23. At 5-year, about half of them developed psychosis23, in line with the meta-analytical prognostic outcomes observed in these groups25. The study further elucidated the course of the BLIPS, with recurrent episodes in 11% of cases. Recurrent episodes were associated with an increased risk of psychosis (HR 3.98)23. Finally, the study investigated the prognostic significance of seriously disorganizing or dangerous BLIPS features that represent a distinctive operationalization between different CHR-P instruments (see ADDIN EN.CITE 26). It was shown that these features associated with an extremely high risk of psychosis (89% at 5 years)23. These findings contribute to the recent accumulating evidence pointing to the BLIPS distinctiveness.

Accordingly, the second study focused on the APS subgroup27. This study employed an advanced machine learning method (LASSO) to replicate the first predictive model that was specifically developed for APS-only individuals and included disorganized communication, suspiciousness, verbal memory and a decline in social functioning28. Although the original predictive model did not replicate, both the models supported unusual thought content and suspiciousness, poor social functioning, and verbal memory and fluency, as highly consistent predictors of psychosis onset in the individuals meeting the APS subgroup of the CHR-P28. Inconsistencies between the two models were explained through the impact of recruitment strategies, in line with the above observations. In fact, the authors noted that locally developed models should only be expected to work on samples that are “recruited in the same way”28. These findings suggest that it may be possible to develop and validate predictive models that are specific to each of the specific CHR-P subgroups.

The third study leverages on the above two studies to propose a developmental clinical staging model that focuses on the BLIPS/BIPS and APS subgroups, excluding the GRD subgroup29. The model was based on hierarchical symptom severity across four groups: CHR-P with negative symptoms, CHR-P with moderately severe APS, CHR-P with severe APS and a revised BIPS/BLIPS29. Of relevance, the latter group is considered to be an intermediate outcome category and no longer strictly prodromal as psychotic level symptoms were already present. Accordingly, a variable outcome threshold was employed to define transitions across the different subgroups29. This is of great relevance because the outcome predicted from a CHR-P state (i.e. psychosis development) is currently heterogeneous, including both prediction of a first episode of psychosis across APS individuals and/or prediction of psychotic recurrences given an initial BLIPS/BIPS. Accordingly, the clinical significance of the outcome predicted by recent individualized psychosis-risk calculators ADDIN EN.CITE 30 is dependent on the initial CHR-P stage. For example, the finding that more severe patients (i.e. with higher levels of unusual thought content and suspiciousness, greater decline in social functioning and some cognitive impairments ADDIN EN.CITE 30) who had already suffered from a brief psychotic episode (e.g. BLIPS/ATPD)23 are at higher risk of clinical deterioration and of further psychotic recurrence is not particularly surprising. The model showed some promising validity because each successive subgroup (classified as different stages of the psychotic disorder) had both an incremental rise in time to conversion and also in conversion rates to a higher subgroup level29. Although no formal model validation for clinical practice was conducted, this pilot model holds great potential because it can overcome some of the above conceptual limitations. Altogether, these findings suggest that merging the CHR-P subgroups together into a single CHR entity is not fully justified, as they lay upon different points along the illness trajectory that are better accounted by a clinical staging approach. 

Conclusions
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